Literature DB >> 17061970

Using cervical mucus and other easily observed biomarkers to identify ovulation in prospective pregnancy trials.

Michael J Zinaman1.   

Abstract

To help fulfil the objectives of prospective studies of pregnancy and human development, such as the National Children's Study, there is a need to pinpoint ovulation and conception in a cohort of women. This paper discusses the suitability of using natural and easily observed markers of ovulation for detection of the most likely day of ovulation and conception. Of the biomarkers supported by clinical data, the use of cervical mucus is emphasised as it appears most promising. A considerable amount of data suggests that observation of changes in vaginal discharge from cervical mucus can closely approximate the day of ovulation, is easy to learn and suitable for a large group of women. While this approach could also be cost-effective, a significant drawback may be the learning phase which may take 2-3 instructional sessions for women to fully identify recurring changes across the menstrual cycle.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17061970     DOI: 10.1111/j.1365-3016.2006.00767.x

Source DB:  PubMed          Journal:  Paediatr Perinat Epidemiol        ISSN: 0269-5022            Impact factor:   3.980


  9 in total

1.  Association between peri-conceptional bisphenol A exposure in women and men and time to pregnancy-The HOPE study.

Authors:  Dabin Yeum; Shinyoung Ju; Kyley J Cox; Yue Zhang; Joseph B Stanford; Christina A Porucznik
Journal:  Paediatr Perinat Epidemiol       Date:  2019-08-29       Impact factor: 3.980

2.  Natural procreative technology for infertility and recurrent miscarriage: outcomes in a Canadian family practice.

Authors:  Elizabeth Tham; Karen Schliep; Joseph Stanford
Journal:  Can Fam Physician       Date:  2012-05       Impact factor: 3.275

3.  Impact of instruction in the Creighton model fertilitycare system on time to pregnancy in couples of proven fecundity: results of a randomised trial.

Authors:  Joseph B Stanford; Ken R Smith; Michael W Varner
Journal:  Paediatr Perinat Epidemiol       Date:  2014-09       Impact factor: 3.980

4.  Impact of preconception enrollment on birth enrollment and timing of exposure assessment in the initial vanguard cohort of the U.S. National Children's Study.

Authors:  Joseph B Stanford; Ruth Brenner; David Fetterer; Leslie Palmer; Kenneth C Schoendorf
Journal:  BMC Med Res Methodol       Date:  2015-09-24       Impact factor: 4.615

5.  Pilot test and validation of the peak day method of prospective determination of ovulation against a handheld urine hormone monitor.

Authors:  Christina A Porucznik; Kyley J Cox; Karen C Schliep; Joseph B Stanford
Journal:  BMC Womens Health       Date:  2014-01-08       Impact factor: 2.809

6.  The Home Observation of Periconceptional Exposures (HOPE) study, a prospective cohort: aims, design, recruitment and compliance.

Authors:  Christina A Porucznik; Kyley J Cox; Karen C Schliep; Diana G Wilkins; Joseph B Stanford
Journal:  Environ Health       Date:  2016-06-08       Impact factor: 5.984

7.  Associations between sexual habits, menstrual hygiene practices, demographics and the vaginal microbiome as revealed by Bayesian network analysis.

Authors:  Noelle Noyes; Kyu-Chul Cho; Jacques Ravel; Larry J Forney; Zaid Abdo
Journal:  PLoS One       Date:  2018-01-24       Impact factor: 3.240

8.  Compliance with daily, home-based collection of urinary biospecimens in a prospective, preconception cohort.

Authors:  Kyley J Cox; Joseph B Stanford; Brenna E Blackburn; Christina A Porucznik
Journal:  Environ Epidemiol       Date:  2019-06-19

9.  Empowering HIV-infected women in low-resource settings: A pilot study evaluating a patient-centered HIV prevention strategy for reproduction in Kisumu, Kenya.

Authors:  Okeoma Mmeje; Betty Njoroge; Pauline Wekesa; Alfred Murage; Raphael O Ondondo; Sheryl van der Poel; Mary A Guzé; Starley B Shade; Elizabeth A Bukusi; Deborah Cohan; Craig R Cohen
Journal:  PLoS One       Date:  2019-03-06       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.